Notice of Allowability	Application No.	Applicant(s)
	09/623,364	KHOMUTOV ET AL.
	Examiner	Art Unit
	Everett White	1623
The MAILING DATE of this communication apperall claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this apport of other appropriate communication GHTS. This application is subject to	plication. If not included will be mailed in due course. THIS
1. This communication is responsive to <u>communication filed J</u>	lune 30, 2005.	
2. The allowed claim(s) is/are <u>1,2,4-7 and 12-14</u> .		
3. A The drawings filed on <u>01 September 2000</u> are accepted by	the Examiner.	
 4. Acknowledgment is made of a claim for foreign priority un a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of the priority documents have International Bureau (PCT Rule 17.2(a)).	been received. been received in Application No cuments have been received in this of this communication to file a reply	national stage application from the
noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. A SUBSTITUTE OATH OR DECLARATION must be submit INFORMAL PATENT APPLICATION (PTO-152) which give	itted. Note the attached EXAMINER	
 6. CORRECTED DRAWINGS (as "replacement sheets") must (a) including changes required by the Notice of Draftsperson 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the depose attached Examiner's comment regarding REQUIREMENT F. 	on's Patent Drawing Review (PTO- s Amendment / Comment or in the C 84(c)) should be written on the drawing the header according to 37 CFR 1.121(c	Office action of angs in the front (not the back) of d). nust be submitted. Note the
Attachment(s) 1. Notice of References Cited (PTO-892) 2. Notice of Draftperson's Patent Drawing Review (PTO-948) 3. Information Disclosure Statements (PTO-1449 or PTO/SB/06 Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ☑ Interview Summary Paper No./Mail Dat 7. ☑ Examiner's Amenda 8. ☑ Examiner's Stateme 9. ☐ Other	e <u>Aug. 11, 2005</u> .

Application/Control Number: 09/623,364

Art Unit: 1623

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on June 3, 2005 has been entered.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Mark Konieczky on Ausgust 3, 2005.

The application has been amended as follows:

Claim 4, line 5, the term "fragments" has been deleted.

Claim 7, line 2, the phrase "function containing group" has been changed to -- cyclodextrin --.

Claim 7, line 4, the "alkoxyl-" has been changed to - - alkoxy- - -.

Claims 17-19 have been deleted.

Reasons For Allowance

The following is an examiner's statement of reasons for allowance: The reason for indicating allowable subject matter is that the prior art of record does not teach or fairly suggest an aminooxy-cyclodextrin of the formula 1 set forth in instant Claim 1 and aminooxy protected derivatives thereof. Upon reconsideration, it was agreed that the Varaprasad et al reference (Bioorganic Chemistry, Vol. 14, pages 8-16, (1986)) does not set forth an aminooxy protected derivative of an aminooxy-cyclodextrin compound.

Art Unit: 1623

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

E. White

James O. Wilson

Supervisory Primary Examiner

Technology Center 1600